Ibudilast

异丁司特

Report date: 2025/05/22 15:54:55
NME

Base Information

Drug NameIbudilast
Drug Alias NameIbudilastum异丁地特异丁斯特IbinalKetas +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytokines modulatorsMacrophage migration inhibitory factor inhibitorsNitric oxide synthase inhibitors +[8] 
TargetsPlatelet-activating factorLeukotriene receptor3',5'-cyclic phosphodiesterase +[8] 
Therapy Area/IndicationsOpioid-Related DisordersAlcoholismSubstance-Related Disorders +[12] 
Global Approved IndicationsNeuralgiaMultiple SclerosisAsthma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesKyorin Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOregon Health And Science UniversityKyorin Pharmaceutical Co LtdMedicinova Inc +[6] 
Inactive CompaniesNew York State Psychiatric InstituteAvigen IncUniversity Of Adelaide
Active IndicationsAlcoholismSubstance-Related DisordersNeuralgia +[7] 
Inactive IndicationsOpioid-Related DisordersDiabetic NeuropathiesHeadache Disorders, Secondary +[5] 

Other Information

ATC CodeR03DC04
Related LinksWikipediaDrugBankKEGG